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Abstract
Introduction: The purpose of this study was to elucidate the effects of histone deacetylase inhibition on the
phenotype and function of dendritic cells and on arthritis in SKG mice.
Methods: Arthritis was induced in SKG mice by zymosan A injection. Trichostatin A, a histone deacetylase inhibitor,
was administered and its effects on arthritis were evaluated by joint swelling and histological evaluation. Interleukin-17
production in lymph node cells was determined by an enzyme-linked immunosorbent assay (ELISA). Foxp3 expression
in lymph node cells and the phenotypes of splenic dendritic cells were examined by fluorescence-activated cell sorting
(FACS). Bone marrow-derived dendritic cells (BM-DC) were generated with granulocyte macrophage colony-stimulating
factor. The effects of trichostatin A on cell surface molecules, cytokine production, indoleamine 2,3-dioxygenase (IDO)
expression and T cell stimulatory capacity were examined by FACS, ELISA, quantitative real-time polymerase chain
reaction and Western blot, and the allo-mixed lymphocyte reaction, respectively.
Results: Trichostatin A, when administered before the onset of arthritis, prevented SKG mice from getting arthritis.
Trichostatin A treatment also showed therapeutic effects on arthritis in SKG mice, when it was administered after the
onset of arthritis. Trichostatin A treatment reduced Th17 cells and induced regulatory T cells in lymph node, and also
decreased co-stimulatory molecule expression on splenic dendritic cells in vivo. In vitro, trichostatin A markedly
suppressed zymosan A-induced interleukin-12 and interleukin-6 production by BM-DC and up-regulated IDO expression
at mRNA and protein levels. Trichostatin A-treated BM-DC also showed less T cell stimulatory capacity.
Conclusions: Histone deacetylase inhibition changes dendritic cells to a tolerogenic phenotype and ameliorates
arthritis in SKG mice.
Introduction
Rheumatoid arthritis is a chronic inflammatory disorder,
characterized by cellular infiltration of and proliferation
in the synovium, leading to the progressive destruction
of the joints. Dendritic cells, monocytes, T cells, B cells,
and neutrophils infiltrate the synovium and interact
with each other to induce chronic synovitis [1,2].
Dendritic cells are efficient antigen-presenting cells,
and develop innate and adaptive immune responses
through interactions with T cells [3]. Dendritic cells
determine the fate of T cell differentiation through the
cytokines they produce; IL-12 induces Th1 cells, the
combination of IL-6, IL-23, and TGF-b induces Th17
cells, and TGF-b induces regulatory T cells (Treg) [3,4].
Recently, Th17 cells have been shown to play a major
role in both human and mouse arthritis [5-7]. Moreover,
CD4
+ T cells activated by dendritic cells express RANKL
and facilitate osteoclast development, leading to bone
erosion in joints with rheumatoid arthritis [8]. It is
hypothesized that dendritic cells are activated by
unknown stimuli in peripheral tissues, and migrate into
the lymph nodes, where they induce T cells to proliferate.
Activated T cells, as well as dendritic cells, migrate into
the joints and induce inflammatory processes, including
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IL-6, resulting in the characteristically pathological joint
damage [9]. In fact, dendritic cells accumulate in the
perivascular area in close association with T and B cells
in the synovium of joints with rheumatoid arthritis [10].
Thus, dendritic cells are thought to be involved in both
initiating and shaping the immune responses in rheuma-
toid arthritis pathology.
Dendritic cells have been shown to regulate as well as
elicit the immune response; those cells with regulatory
properties are called tolerogenic dendritic cells. The tol-
erogenic dendritic cells regulate the immune responses
by inducing T cell anergy, inducing Treg, or activating
Th2 cells [11]. The characteristics of tolerogenic dendri-
tic cells are as follows: 1) lower expression of cell sur-
face molecules such as CD80 and CD86, 2) a higher
expression of indoleamine 2,3-dioxygenase (IDO), 3)
decreased secretion of cytokines related to the innate
immune response, and 4) lower T cell stimulation capa-
city [12,13]. Various attempts have been made to gener-
ate tolerogenic dendritic cells and endogenous- or in
vitro-generated tolerogenic dendritic cells have been
injected in vivo for treating autoimmune disease, illus-
trating that dendritic cells are now considered as target
cells in inflammatory conditions [14].
Histone deacetylase inhibitors (HDAi), such as
trichostatin A (TSA) and suberoylanilide hydroximic
acid, are small molecule compounds that exert anti-
proliferative effects on various tumor cells and are cur-
rently used as anti-cancer drug [15]. Histone deacetylase
inhibitors are also potential therapeutic agents for rheu-
matoid arthritis because HDAi suppress joint swelling,
synovial inflammation, and subsequent bone and
cartilage destruction in animal models of rheumatoid
arthritis [16-18]. The mechanism of anti-rheumatic
activity by HDAi has been ascribed to the suppression
of proliferation and function of synovial fibroblasts. In
fact, we have shown the growth-inhibitory effects of
HDAi on rheumatoid arthritis-synovial fibroblasts
in vitro [19]. Recently, however, HDAi have been
reported to have immunoregulatory effects along with
anti-tumor effects. We and others have shown that
HDAi alter the phenotype and cytokine production of
dendritic cells, as well as differentiation of monocytes
into dendritic cells [20,21].
To clarify the immunoregulatory role of HDAi in a
mouse arthritis model, we examined the effect of an
HDAi (TSA) on SKG mice, a T cell-mediated model of
chronic arthritis. We also examined the effects of TSA
on the phenotypes and functions of mouse bone
marrow-derived dendritic cells (BM-DC). Here, we show
the regulatory effects of TSA on dendritic cells in vitro,
as well as the preventive and therapeutic effects on
arthritis in vivo.
Materials and methods
Animals
Female SKG mice and female C57BL/6 mice were
obtained from CLEA Japan, Inc. (Osaka, Japan). Both
t h eS K Ga n dC 5 7 B L / 6m i c ew e r eh o u s e di nt h eK o b e
University animal facility at a constant temperature and
were provided laboratory chow and water ad libitum.
All procedures were carried out in accordance with the
recommendations of the Institutional Animal Care
Committee of Kobe University.
Reagents and antibodies
Zymosan A (ZyA), dimethyl sulfoxide (DMSO), phorbol
myristate acetate (PMA), suberoylanilide hydroximic
acid, ionomycin, bovine serum albumin, 2-mercapto-
ethanol (2-ME), and saponin were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Phosphate-buffered
saline was from Nissui Pharmaceutical Co., Ltd. (Tokyo,
Japan). Trichostatin A (TSA), 4% paraformaldehyde
phosphate buffer solution, hematoxylin and eosin, RPMI-
1640 with L-glutamine, phenol red, and HEPES were
from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan). EDTA (Dojindo Laboratories, Kumamoto, Japan),
fetal bovine serum (MP Biomedicals, Inc., Illkirch,
France), 1% penicillin-streptomycin (Lonza Walkersville,
Inc., Walkersville, MD, USA), recombinant murine
granulocyte macrophage colony-stimulating factor
(Peprotech, Rocky Hill, NJ, USA) were also purchased.
The PE-anti-mouse FOXP3 Flow kit and allophycocyanin
(APC)/Cy7-anti-mouse CD8a were purchased from Bio-
Legend, San Diego, CA, USA. Phycoerythrin (PE)-anti-
mouse CD80, PE-anti-mouse CD86, PE-anti-mouse
CD40, PE- anti-mouse MHC class II (I-E(k)), fluorescein
isothiocyanate (FITC)-anti-mouse B220, FITC-anti-
mouse CD25, FITC-anti-mouse CD80, FITC-anti-mouse
CD86, FITC-anti-mouse CD40, FITC-anti-mouse MHC
class II (I-A/I-E), FITC-anti-mouse CD54, allophycocya-
nin (APC)-anti-mouse CD11c, and APC-anti-mouse CD4
were purchased from eBioscience (San Diego, CA, USA).
Induction of arthritis
SKG mice that were seven or eight weeks old were
intraperitoneally injected with 2 mg/mouse ZyA, as pre-
viously described [22]. Briefly, ZyA suspended in saline
was kept in boiling water for 10 minutes and the ZyA
solution (0.5 ml/mouse) was intraperitoneally injected
into SKG mice. Arthritis developed between 14 and 21
days after injection.
Treatment of SKG mice with trichostatin A
Trichostatin A (8 mg/kg) was dissolved in DMSO and
subcutaneously administered to SKG mice from Day 14
(before the onset of arthritis) to Day 22 (after the onset
of arthritis). DMSO was used as a control.
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Arthritis severity was evaluated according to the clinical
arthritis scores as follows: 0, no joint swelling; 0.1, swel-
ling of one finger joint; 0.5, mild swelling of wrist or
ankle; 1.0, severe swelling of wrist or ankle, as previously
reported [23]. Arthritis scores for all the digits of the
forepaws and hind paws, as well as for the wrists and
ankles, were totaled for each mouse. The maximum
possible clinical arthritis score is 5.8.
Histology
Mice were killed on Day 35 after the administration of
ZyA. Control mice injected with DMSO were killed at
the same time. After the groups of mice were killed,
their hind paws were removed, fixed in 4% paraformal-
dehyde in phosphate-buffered saline, decalcified in
EDTA, embedded in paraffin, and sectioned. The
samples were then stained with hematoxylin and eosin.
Histologic evaluation was performed by the scoring sys-
tem described previously, in which 0 = no inflammation,
1 = slight thickening of the synovial cell layer and/or
some inflammatory cells in the sublining, 2 = thickening
of the synovial lining, infiltration of the sublining, and
localized cartilage erosions, and 3 = infiltration in the
synovial space, pannus formation, cartilage destruction,
and bone erosion [24].
IL-17 production and Foxp3 expression in SKG mice
Inguinal lymph node cells (1.0 × 10
6 cells/ml) were col-
lected and stimulated with PMA + ionomycin and the
IL-17A levels in the supernatants were determined by
an enzyme-linked immunosorbent assay (ELISA)
(SABiosciences, Frederick, MD, USA), following the
manufacturer’s instructions. Inguinal lymph node cells
from both the DMSO-treated and TSA-treated SKG
mice were collected on Day 35 and then were ground
using the inner cylinder of a syringe on the cell strainer
(BD Biosciences Pharmingen, San Jose, CA, USA) in a
3.5-cm Petri dish. The cells were stained with APC-anti-
CD4, FITC-anti-CD25, and PE-intracellular Foxp3
monoclonal antibodies according to the manufacturer’s
protocol. Foxp3 expression on gated CD4
+CD25
+T cells
was determined by flow cytometry.
Analysis of conventional splenic dendritic cells in SKG
mice with fluorescence-activated cell sorting
Splenic cells from both the DMSO-treated and
TSA-treated SKG mice were collected on Day 35 and
treated with ACK lysing buffer (Lonza Walkersville, Inc.)
to lyse red blood cells at 4°C for five minutes, followed by
washing twice with 0.5% bovine serum albumin in
phosphate-bufferd saline. The cells were incubated with
the indicated monoclonal antibodies (FITC-anti-B220,
APC-anti-CD11c, APC/Cy7-anti-mouse CD8a and
PE- anti-CD80 or PE-anti-CD86 or PE-anti-CD40 or
PE-anti-MHC class II) for 30 minutes at 4°C. Isotype-
matched antibodies were used as controls, and Fc block
(BD Biosciences Pharmingen) was used to block non-
specific binding to Fc receptors. After extensive washing,
the cells were stained with 7AAD (BD Biosciences
Pharmingen). The cells were analyzed on a FACSCalibur
or a FACS Canto II flow cytometer (Becton Dickinson,
San Jose, CA, USA) at the CD11c
high-B220
negative gate to
define conventional dendritic cells. Data were expressed
as the mean fluorescence intensity and/or as the percen-
tage (%) of positive cells after subtraction of background
isotype-matched values.
Generation of bone marrow-derived dendritic cells
Bone marrow-derived dendritic cells (BM-DC) were
generated from SKG mice. Briefly, bone marrow cells
were collected from the SKG mouse femur, and 1.0 × 10
6
bone marrow cells were cultured in a 24-well plate with
RPMI-1640 supplemented with 10% fetal bovine serum,
1% penicillin-streptomycin, 100 μM2 - M E ,a n d5 0n g / m l
recombinant murine granulocyte macrophage colony-
stimulating factor. The medium were changed every two
days. On Day 8, weakly adherent cells were harvested
using 4°C PBS as BM-DC [25].
Cell surface molecules of bone marrow-derived dendritic
cells
Bone marrow-derived dendritic cells were generated as
mentioned above and stimulated with ZyA (5 μg/ml),
TSA (20 nM), or ZyA+TSA for the last 48 h. Cells were
harvested and incubated with the indicated monoclonal
antibodies (APC-anti-CD11c and FITC-anti-MHC class
II, FITC-anti-CD54, FITC- anti-CD80, FITC-anti-CD86,
or FITC-anti-CD40) for 30 minutes at 4°C. Cells were
stained and analyzed at the CD11c
high gate using the
FACSCalibur as previously described.
Enzyme-linked immunosorbent assay
Bone marrow-derived dendritic cells (1.0 × 10
6 cells/ml)
were stimulated with ZyA (5 μg/ml), TSA (20 nM), or
ZyA + TSA for 18 h and the IL-12p70, IL-12p40, and
IL-6 levels in the culture supernatant were measured
with commercial ELISA kits (BD Biosciences, San
Diego, CA, USA) following the manufacturer’s
instructions.
Quantitative real-time polymerase chain reaction
Levels of IDO1 and IDO2 mRNA expression were
determined by quantitative real-time polymerase chain
reaction. Total RNAs were isolated using an RNeasy
Mini kit (Qiagen, Tokyo, Japan) and cDNA synthesis
was performed using Super Script III First-Strand Synth-
esis System for RT-PCR (Invitrogen, Carlsbad, CA,
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SYBR Green Gene Expression Assay (Qiagen) accord-
ing to the manufacturer’s protocol. The primer pairs
used in the reactions were purchased from Qiagen
(QT00103936 for IDO1 and QT01066345 for IDO2).
The amplification reactions, data acquisition, and ana-
lyses were performed with the ABI Prism 7900 HT
instrument (Applied Biosystems, Foster city, CA, USA).
Glyceraldahyde-3-phosphate dehydrogenase (GAPDH,
Qiagen QT01658692) was used as the housekeeping
gene against which all of the samples were normalized
for differences in the amount of total RNA added to
each cDNA reaction and for the variation in the
reverse transcriptase efficiency among the different
cDNA reactions.
Western blot analysis
Bone marrow-derived dendritic cells were harvested
after stimulation with ZyA (5 μg/ml), TSA (20 nM),
o rZ y A+T S Af o r4 8ha n dl y s e dw i t hR I P Ab u f f e r
(Thermo Scientific, Rockford, IL, USA) containing
protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany) at 4°C for 30 minutes. After
centrifugation at 12,000 × g for 15 minutes, the super-
natants were removed and the protein concentrations
were determined using the BCA Protein Assay
Reagent (Pierce Chemical Company, Rockford, IL,
USA). Samples containing 10 to 30 μgo fp r o t e i n s
were boiled for five minutes in sodium dodecyl sulfate
sample buffer (Wako Pure Chemical Industries, Ltd.).
The expression of IDO was determined by immuno-
blot analysis using purified anti-mouse IDO antibody
(BioLegend).
Allo-mixed lymphocyte reaction
Naïve CD4
+T cells from C57BL/6 mice were purified by
positive selection using anti-CD4
+CD62L magnetic
beads (Miltenyi Biotec, Bergisch Gladbach, Germany).
Bone marrow-derived dendritic cells from SKG mice
were harvested and purified by positive selection using
anti-CD11c+ magnetic beads (Miltenyi Biotec,).
Naïve CD4
+T cells (1.0 × 10
5/200 μl) were co-cultured
with 2.0 × 10
4 control dendritic cells, ZyA (5 μg/ml)
dendritic cells, TSA (20 nM) dendritic cells, or ZyA +
TSA dendritic cells derived from SKG mouse bone
marrow. On Day 5, cell proliferation was determined by a
cell proliferation ELISA kit (Roche, Penzberg, Germany),
using BrdU and anti-BrdU antibodies.
Statistical analysis
Results are expressed as the mean ± standard error of
the mean (SE). Statistical comparisons were performed
by Student’s t-test. Differences were considered signifi-
cant when P < 0.05.
Results
Preventive effects of trichostatin A on SKG mice
We initially examined the preventive effects of TSA on
arthritis in SKG mice, an animal model of chronic
arthritis that shows a pathology similar to that of
rheumatoid arthritis. Zymosan A was administered to
SKG mice on Day 0 and DMSO (n =5 )o rT S A8m g / k g
(n = 5) was subcutaneously injected from Day 14 through
Day 42 (for 28 days of treatment). The clinical arthritis
scores of the TSA-treated groups were significantly lower
than those of the DMSO-treated groups, indicating
the preventive effects of TSA on arthritis in SKG mice
(Figure 1).
We next examined the histological differences
between the TSA-treated and control groups. Mice were
killed on Day 35 (treatment for 21 days). In the control
group, synovial hyperplasia and erosion of articular
cartilage and bone were more severe than in the TSA-
treated group, as depicted in Figure 2A. The comparison
of the histological arthritis scores between these groups
clearly showed again the preventive effects of TSA on
arthritis in proportion to the clinical arthritis scores
(P = 0.0004) (Figure 2B).
The effects of trichostatin A on IL-17 production and
Foxp3 expression by inguinal lymph node cells
We next examined the effect of TSA on IL-17A produc-
tion, because IL-17 plays a central role in the induction
of severe arthritis in SKG mice [26]. Inguinal lymph
node cells from SKG mice were stimulated with PMA/
ionomycin and IL-17A in the supernatant was deter-
mined by ELISA. IL-17A production by lymph node
cells in the TSA group was remarkably reduced
Figure 1 The effects of trichostatin A on SKG mice.Z y m o s a nA
was administered to SKG mice. Dimethyl sulfoxide or trichostatin A
was injected subcutaneously daily for 28 days (Day 14 through Day
42). The clinical arthritis scores were evaluated and the results
are expressed as the mean ± SE (DMSO group: n = 5, TSA group:
n = 5). * P < 0.05.
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strating that TSA suppresses the development of Th17
cells in vivo in SKG mice.
We also examined whether TSA affected the Treg popu-
lation in SKG mice. Foxp3 expression in inguinal lymph
node cells on Day 35 from the control- and TSA-treated
SKG mice were determined by fluorescence activated cell
sorting (FACS). We found significant increase in the
ratio of CD4
+ CD25
+ Foxp3
+ cells among CD4
+ cells in
TSA-treated group compared to control group, suggesting
that Treg are involved in the prevention of arthritis in
SKG mice with TSA (Figure 3B).
The effects of trichostatin A on the phenotype
of splenic dendritic cells
Histone deacetylase inhibitors have been shown to
block Th17 cells induction by altering dendritic cell
function [27]. Thus, we hypothesized that TSA alters
dendritic cell function and reduces Th17 cell genera-
tion in SKG mice and we examined the cell surface
molecules on conventional dendritic cells in spleen.
Spleen cells were used because the number of cells
obtained from the lymph nodes was too small for
FACS analysis. The mice in both the control and TSA-
treated groups were killed on Day 35 (treatment for 21
days) and spleen cells were collected and analyzed
using FACS, as described in the Materials and methods
section. A gate was set on conventional dendritic cells,
which are CD11c
high and B220
negative cells, and the
surface expression of various molecules was examined.
There was no significant difference in the ratio of
CD8a
+ and CD8a
- conventional dendritic cell subtypes
(data not shown). In the CD8a
+ conventional dendritic
cell subset, the expressions of CD86, CD80, and CD40
were significantly decreased in the TSA-treated group
compared to the control group (Figure 4A, B), demon-
strating the in vivo effects of TSA on conventional dendri-
tic cells. In contrast, there were no significant differences
in the expression of these molecules in the CD8a
- conven-
tional dendritic cell subset (data were not shown). Thus,
TSA predominantly affects CD8a
+ conventional dendritic
cells in vivo.
The effects of trichostatin A on cytokine production
of zymosan A-treated dendritic cells in vitro
We found that TSA ameliorates severe arthritis in
terms of both clinical and histological scores and mod-
ulates the conventional dendritic cell phenotype and
Th17 cell generation in vivo. To further clarify the
immune-regulatory functions of TSA, we examined the
effects of TSA on the ZyA-treated dendritic cells in
vitro. Bone marrow-derived dendritic cells were gener-
ated from SKG mice as described in Materials and
methods. On Day 7, the cells were pulsed with ZyA
(5 μg/ml), TSA (20 nM), or ZyA + TSA for 18 h. The
cells and supernatants were collected. The IL-12p70,
IL-12p40, and IL-6 cytokine levels expressed by ZyA-
treated dendritic cells in the supernatant were signifi-
cantly decreased in the presence of TSA, indicating
that TSA inhibits the ZyA-induced production of these
cytokines (Figure 5A).
Figure 2 Histological analysis of SKG mice on Day 35 (after 21
days of treatment).( A) The histological analysis was performed on
their hind paw sections stained by hematoxylin and eosin. Tissues
are shown at ×40 magnification. Representative results are shown.
(B) Histological arthritis scores between the dimethyl sulfoxide- and
trichostatin A-treated groups of SKG mice. Mice were killed on Day
35 (treatment for 21 days) and the histological arthritis scores were
calculated on their left hind paw. Results are expressed as the mean
± SE (DMSO group: n = 8, TSA group: n =8 ,P = 0.0004). CAS,
clinical arthritis scores.
Figure 3 Production of IL-17A and expression of Foxp3 by
inguinal lymph node cells of SKG mice.( A) Inguinal lymph node
cells of SKG mice in each group were collected on Day 35. Cells
were stimulated with phorbol myristate acetate/ionomycin and the
supernatants were collected after 8 h for the measurement of IL-
17A. Values are presented as the mean ± SE (DMSO group: n =3 ,
TSA group: n =3 ,P < 0.0001). (B) The expression of Foxp3 in
inguinal lymph node cells in SKG mice. Inguinal lymph node cells of
SKG mice were collected on Day 35 in each group as previously
described. Cells were stained for anti-CD4, anti-CD25, and Foxp3.
The percentage of CD4
+CD25
+Foxp3
+ cells among gated CD4
+ cells
was determined. Results are expressed as the mean ± SE (DMSO
group: n = 4, TSA group: n =4 ,P = 0.038).
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expression in bone marrow-derived dendritic cells
IDO1 and IDO2 expression in BM-DC were determined
using real-time polymerase chain reaction. Both IDO1
and IDO2 are rate-controlling enzymes related to tryp-
tophan metabolism and tryptophan depletion in the
microenvironment has been reported to suppress cell
proliferation [28,29]. Thus, IDO1 and IDO2 expressions
in dendritic cells suppress the T cell reaction through
tryptophan depletion. We examined the mRNA expres-
sion of IDO1 and IDO2 in BM-DC and found that TSA
or ZyA alone induced IDO marginally, but the combina-
tion of TSA and ZyA markedly induced mRNA expres-
sion of IDO1 and IDO2 (Figure 5B). Western blot
analysis confirmed the induction of IDO expression by
BM-DC with the combination of ZyA and TSA at the
protein level (Figure 5C). Protein expression levels of
IDO were similar to the mRNA levels of IDO2.
The effects of trichostatin A on cell surface molecules
of bone marrow-derived dendritic cells
We analyzed cell surface expressions on BM-DC treated
with ZyA (5 μg/ml), TSA (20 nM), or ZyA + TSA. After
48-h treatment, cell surface expressions of MHC class II,
CD54, CD86, CD80, and CD40 on BM-DC were deter-
mined by FACS as described in Materials and methods.
All these molecules were remarkably up-regulated after
treatment with ZyA compared with those of the non-sti-
mulated group (control). However, the expression of
CD86 and CD40 were significantly down-regulated in the
presence of TSA. Cell surface expressions of MHC class
II, CD54, and CD80 did not differ between ZyA-treated
and ZyA+TSA-treated BM-DC (Figure 6A, B). We failed
to show the effect of TSA on CD80 expression in vitro,
probably because the maturation stage may be different
from dendritic cells in vivo.
The effects of trichostatin A on dendritic cell-induced
T cell proliferation
We next tested the ability of TSA-treated dendritic cells
to stimulate T cells by allo-mixed lymphocyte reaction.
Bone marrow-derived dendritic cells from SKG mice
were mixed with CD4
+ naïve T cells from C57BL/6
mice spleen. Pretreatment of BM-DC with ZyA alone
augmented T cell proliferation, but co-treatment with
Z y Aa n dT S Ar e s u l t e di nr e d u c e dTc e l lp r o l i f e r a t i o n
compared to that with ZyA alone, indicating that TSA
inhibited the ZyA-induced T cell stimulatory capacity of
BM-DC (Figure 7). The results of the series of in vitro
experiments indicated that TSA skewed dendritic cell
function toward a tolerogenic phenotype.
Therapeutic effects of trichostatin A on arthritis
in SKG mice
Finally, we examined the effect of TSA on SKG mice
after the onset of arthritis. Arthritis was induced as
described and TSA treatment was started on Day 22,
when the arthritis scores had reached approximately 1.
Trichostatin A treatment exhibited an inhibition of the
worsening of clinical arthritis scores compared with
DMSO, demonstrating the therapeutic effect of TSA on
arthritis (Figure 8).
Discussion
Our results have clearly shown that TSA ameliorates
arthritis in SKG mice. The effects were characterized by
a down-regulation of Th17 cells as well as up-regulation
of Treg. We assumed that dendritic cells play a critical
role in this model because it is well known that ZyA
activates dendritic cells via the Dectin-1 and Toll-like
receptor (TLR)-2 pathway [30,31]. Considering the sig-
nificance of dendritic cells in determining Th cell differ-
entiation, we examined the effects of TSA on dendritic
Figure 4 MHC class II, CD86, CD80, and CD40 expression on
CD8a
+ splenic conventional dendritic cells. Spleen cells were
isolated from dimethyl sulfoxide- or triclostatin A-treated SKG mice
on Day 35 and stained for each marker. Gates were set on CD8a
+
conventional dendritic cells and cell surface molecules were
analyzed on fluorescence-activated cell sorting. (A) Representative
results of four experiments are shown by mean fluorescence
intensity. (B) The mean fluorescence intensities of indicated
molecules in each group were compared. Results are expressed as
the mean ± SE (DMSO group: n = 4, TSA group: n =4 ,P-value was
N.S. in MHC class II, P = 0.035 in CD80, P = 0.023 in CD86, P = 0.012
in CD40). N.S., not significant.
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liorated arthritis, at least in part, by inhibiting dendritic
cell activation.
Some reports have shown a therapeutic effect of HDAi
on arthritis in mice; antibody-induced arthritis, collagen-
induced arthritis, and adjuvant-induced arthritis have all
been successfully treated with various HDAi [16-18].
Previous reports have shown that HDAi induce p21 in
synovial fibroblasts, protect against cartilage apoptosis,
inhibit matrix metalloproteinase production, and up-reg-
ulate Treg in vivo [17,32,33]. However, this is the first
report to demonstrate that HDAi can ameliorate arthri-
tis in a mouse model through regulating dendritic cells.
Our in vitro experiments indicated that HDAi skewed
dendritic cell function to a tolerogenic-like phenotype.
Zymosan A induced maturation of BM-DC, up-regulat-
ing expression of cell surface molecules, cytokine
production, and T cell stimulation. When dendritic cells
were stimulated with ZyA in the presence of TSA, a sig-
nificant decrease was observed in the cytokine produc-
tion, expressions of co-stimulatory molecules, and T cell
stimulatory capacity, and a significant up-regulation
of IDO gene and protein expression was also observed.
Tolerogenic dendritic cells present antigens to antigen-
specific T cells, but fail to deliver adequate co-stimula-
tory signals for effector T cell activation and proliferation
[11]. Trichostatin A-treated dendritic cells in vitro are
similar to tolerogenic dendritic cells in that they produce
low levels of cytokines and high levels of IDO, but are
different in that the expression of co-stimulatory mole-
cules (CD80) is not markedly reduced. Thus, we consider
that HDAi alter dendritic cells to a tolerogenic-like phe-
notype. Some previous reports have reported that histone
deacetylase (HDAC) inhibition alters dendritic cell func-
tion when lipopolysaccharide was used to stimulate and
differentiate dendritic cells [34]. We have found similar
results using ZyA, which signals through Dectin-1 and
TLR-2, instead of lipopolysaccharide, which utilizes
TLR-4, illustrating that HDAC inhibition alters dendritic
cell function regardless of the stimulation. Interestingly,
activation of the Dectin-1 pathway has been shown to
lead to the generation of Th17 cells, rather than Treg,
Figure 5 The effects of trichostatin A on bone marrow-derived dendritic cells.( A) The effects of trichostatin A on cytokine production by
bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells were generated from SKG mice and stimulated for 18 h with zymosan
A and/or triclostatin A. The concentrations of IL-12p70, IL-12p40, and IL-6 in the supernatant were measured by an enzyme-linked
immunosorbent assay. Values are presented as the mean ± SE (n = 3). Data are representative of two (IL-12p70) or three (IL-12p40 and IL-6)
independent experiments with similar results (P = 0.027 in IL-12p70, P = 0.024 in IL-12p40, P = 0.029 in IL-6). (B) The effects of triclostatin A on
indoleamine 2,3-dioxygenase mRNA expression by bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells were generated
from SKG mice and stimulated for 18 h with zymosan A (5 μg/ml) and/or trichostatin A (20 nM). IDO1 and IDO2 mRNA expression was
measured by quantitative real-time polymerase chain reaction. Representative results of two independent experiments are shown. (C) The effect
of trichostatin A on indoleamine 2,3-dioxygenase production by bone marrow-derived dendritic cells. Bone marrow-derived dendritic cells were
stimulated with zymosan A (5 μg/ml) and/or trichostatin A (20 nM) for 48 h. Cell lysates were analyzed by Western blotting with anti-
indoleamine 2,3-dioxygenase antibodies. The blot is representative of two independent experiments.
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that TSA suppresses the Dectin-1 pathway in dendritic
cells, resulting in decreased Th17 cell generation.
Dendritic cells regulate CD4
+T cell differentiation and
the immune response. Interleukin-12 is a key cytokine
in Th1 cell differentiation and IL-6 is key in Th17 cell
differentiation [37]. Tumor growth factor-b and retinoic
acid induce Treg [38]. Our in vivo results demonstrated
that TSA treatment markedly reduced Th17 cell popula-
tion and slightly up-regulated Treg. Considering a larger
effect of TSA on IL-17 production, TSA appears to have
ameliorated arthritis in mice primarily by inhibiting the
dendritic cell activation by ZyA because it has been
shown that TSA and suberoylanilide hydroximic acid
suppress Th17 cell differentiation by altering dendritic
cell function [27]. Consistent with our results, some
reports have shown the induction of Treg by HDAi
treatment in vivo [33,39]. It is difficult to explain how
TSA induces Treg in vivo. First, it is difficult to deter-
mine which subset of Treg, natural Treg or induced
Treg, was derived by TSA in SKG mice [40-43]. More-
over, TSA might directly induce Treg through acetyla-
tion of Foxp3 or TSA might modulate dendritic cell
function to indirectly induce Treg [44]. We have failed
to determine the direct effects of TSA on Th cell differ-
entiation in vitro because TSA suppressed naïve CD4
+ T
cell proliferation so strongly as to prevent examination
of the functional differentiation.
In mice, conventional dendritic cells that reside in
lymphoid tissue can be separated into CD8a
+ and
CD8a
- conventional dendritic cells [45,46]. We observed
Figure 6 The effects of trichostatin A on the phenotype of
bone marrow-derived dendritic cells. Bone marrow-derived
dendritic cells were generated from SKG mice and incubated for 48
h with zymosan A and/or trichostatin A. Bone marrow-derived
dendritic cells were stained for anti-MHC class II, anti-CD54, anti-
CD86, anti-CD80, and anti-CD40. (A) The fluorescence activated cell
sorting was shown by mean fluorescence intensity. Data are
representative of three independent experiments. (B) The mean
fluorescence intensity of each group was compared. Results are
expressed as the mean ± SE of three independent experiments (P-
values were N.S. in MHC class II, CD54 and CD80, P = 0.012 in CD86,
P = 0.034 in CD40). N.S, not significant.
Figure 7 The effects of trichostatin A on the T cell stimulatory
capacity of dendritic cells. Bone marrow-derived dendritic cells
from SKG mice were treated with zymosan A and/or trichostatin A
for 18 h, extensively washed, and used for the allo-mixed
lymphocyte reaction to assess the T cell stimulatory capacity. Results
are expressed as the mean ± SE of four independent experiments
(P < 0.01).
Figure 8 Therapeutic effects of trichostatin A after the onset of
arthritis in SKG mice. SKG mice were treated with dimethyl
sulfoxide or trichostatin A on Day 22, when the mean clinical
arthritis score was nearly 1.0 for 24 days. Results are expressed as
the mean ± SE (DMSO group: n = 8, TSA group: n = 8). * P < 0.05.
N.S., not significant.
Misaki et al. Arthritis Research & Therapy 2011, 13:R77
http://arthritis-research.com/content/13/3/R77
Page 8 of 11that TSA treatment in vivo significantly down-regulated
co-stimulatory molecules on the CD8a
+ conventional
dendritic cell subset, but not on the CD8a
- conventional
dendritic cell subset. Furthermore, TSA tended to
decrease the CD8a
+ conventional dendritic cell popula-
tion compared to DMSO treatment, although the differ-
ence was not statistically significant (data were not
shown). These results suggested that TSA mainly affected
the CD8a
+ conventional dendritic cell population in vivo.
CD8a
+conventional dendritic cells are considered a more
developed or activated form of CD8a
- conventional den-
dritic cells, because CD8a
+ conventional dendritic cells
have been shown to more potently induce CD4
+Tc e l l
proliferation and interferon-g production compared with
similarly activated CD8a
- conventional dendritic cells
[47-49]. Recently, CD8a
+ conventional dendritic cells
have been shown to produce IL-12p70 and induce anti-
gen-specific Th17 and Th1 cells, resulting in the accel-
eration of collagen-induced arthritis [50]. Our results
indicated that TSA treatment altered the CD8a
+ conven-
tional dendritic cell phenotype to that of the tolerogenic
CD8a
+ conventional dendritic cells and inhibited Th17
cell differentiation, leading to the suppression of arthritis
in SKG mice, in which Th17 cells are critically involved
[26]. Thus, we speculate that CD8a
+ conventional
dendritic cells are one of the targets of the immunoregu-
latory effects of TSA.
It has been reported that vasointestinal peptide, IL-10,
TGF-b, and vitamin D can induce tolerogenic dendritic
cells. Histone deacetylase inhibitors are also useful for
inducing tolerogenic dendritic cells in the treatment of
rheumatoid arthritis, as we have shown in this report.
SKG mice do not develop any arthritis in a specific
pathogen-free environment, but develop severe arthritis
after a single administration of ZyA, indicating that
environmental factors contribute to the onset of arthritis
[22]. Because microorganisms activate dendritic cells,
targeting dendritic cell function is a rational way of reg-
ulating the autoimmune response triggered by microor-
ganisms. It is noteworthy that HDAi-treated dendritic
cells have been reported to be useful in the treatment of
g r a f t - v e r s u s - h o s td i s e a s ei nm i c e[ 5 1 ] .T h u s ,t h ep r o -
spects appear promising for dendritic cell-based cell
therapy for rheumatoid arthritis using appropriate
HDAi.
In conclusion, HDAC inhibition ameliorates arthritis
in SKG mice, at least in part, by altering dendritic cell
function into the tolerogenic phenotype. The HDAC
protein family consists of at least 18 HDACs, includ-
ing the sirtuin family of HDACs. Recently, HDAC9
was shown to be involved in Treg regulation [39], and
HDAC11 was shown to be involved in immune toler-
ance by its effect on macrophage function [52].
Further understanding of HDAC functions in dendritic
cells and the development of selective HDAi are
expected to lead to novel therapies that target dendri-
tic cells.
Conclusions
Histone deacetylase inhibition changes dendritic cells to
a tolerogenic phenotype and ameliorates arthritis in
SKG mice.
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